January 24, 2013
U.S. Hepatitis C-Related Health Care Costs to Peak at $9.1B in 2024
As the baby boomer population ages and the silent epidemic of hepatitis C—heavily concentrated in this age group—wreaks havoc on millions of livers, the United States will see a peak of both liver disease and associated health care costs during the next two decades, according to a new report published in the journal Hepatology. The study assumed no incremental rise in treatment rates as a consequence of newer direct acting antiviral therapies.
Among the study’s projections were:
To read the study, click here.
- The prevalence of cirrhotic patients is expected to peak in 2015 with 626,500 cases.
- The prevalence of decompensated cirrhosis should peak in 2019 with 107,400 cases.
- Cases of the liver cancer hepatocellular carcinoma (HCC) will increase to 23,800 cases in 2018 and then decline.
- Active treatment of hepatitis C virus (HCV) can substantially reduce new
infections: If the number of people treated for hep C is doubled to a
constant rate of 126,000 per year between 2012 and 2030 and the average
sustained viral load (SVR, considered a cure) is increased to 70
percent, by 2030 there will be fewer than 100,000 cases of HCV left in
the U.S. (Down from the current estimated 2.5 million cases.)
- Mortality from the disease will increase steadily and peak around 2020.
- In 2011, the total U.S. health care cost for hep C was $6.5 billion.
This burden should peak in 2024 at $9.1 billion, mostly as a result of
liver disease: 46 percent of the cost is due to decompensated cirrhosis,
20 percent to compensated cirrhosis and 16 percent to HCC.
Search: hepatitis C, HCV, hep C, baby boomer, health care costs, liver, journal Hepatology, cirrhotic, decompensated cirrhosis, hepatocellular carcinoma, HCC, sustained viral load, SVR, cure, peak.
Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.
Show comments (0 total)
[Go to top]